Aktis Oncology, INC. (AKTS) — SEC Filings
Latest SEC filings for Aktis Oncology, INC.. Recent S-1 filing on Dec 19, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.
View Aktis Oncology, INC. on SEC EDGAR
Overview
Aktis Oncology, INC. (AKTS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Dec 19, 2025: Aktis Oncology, Inc. (AKTS) is a clinical-stage oncology company focused on expanding targeted radiopharmaceuticals to broader patient populations. The company's proprietary miniprotein radioconjugate platform aims to deliver alpha-emitting radioisotopes to solid tumors with high penetration and rap
Sentiment Summary
Across 1 filings, the sentiment breakdown is: 1 mixed. The dominant filing sentiment for Aktis Oncology, INC. is mixed.
Filing Type Overview
Aktis Oncology, INC. (AKTS) has filed 1 S-1 with the SEC between Dec 2025.
Recent Filings (1)
-
Aktis Oncology Eyes IPO to Advance Radiopharmaceutical Pipeline
— S-1 · Dec 19, 2025 Risk: high
Aktis Oncology, Inc. (AKTS) is a clinical-stage oncology company focused on expanding targeted radiopharmaceuticals to broader patient populations. The company'
Risk Profile
Risk Assessment: Of AKTS's 1 recent filings, 1 were flagged as high-risk, 0 as medium-risk, and 0 as low-risk. The overall risk profile suggests elevated risk that warrants close monitoring.
Key Executives
- Matthew Roden, PhD
Industry Context
The radiopharmaceutical market is experiencing significant growth, projected to reach $26 billion by 2032, driven by the success of targeted therapies like Pluvicto ($1 billion first-year sales) and Padcev ($1.9 billion in 2024 sales). This sector has seen substantial investment, with aggregate transaction values reaching $33 billion over 10 years, indicating strong strategic interest. Aktis Oncology operates within this dynamic landscape, aiming to leverage its proprietary miniprotein platform to expand the reach of alpha-emitting radiopharmaceuticals to broader patient populations with solid tumors.
Top Tags
Biotechnology (1) · Oncology (1) · Radiopharmaceuticals (1) · IPO (1) · Clinical Stage (1) · Nectin-4 (1) · Alpha-emitters (1)
Key Numbers
- Padcev worldwide sales in 2024: $1.9 billion — Validates Nectin-4 as an anticancer target, despite its limited impact beyond UC
- Estimated peak sales for Padcev: $7.0 billion — Highlights the significant commercial potential of Nectin-4 targeting therapies
- Pluvicto first full year sales: $1 billion — Demonstrates rapid adoption and patient impact potential of radiopharmaceuticals
- Estimated global peak sales for Pluvicto in prostate cancer: $4 billion — Illustrates the substantial market opportunity for successful radiopharmaceuticals
- Projected global radiopharmaceuticals market by 2032: $26 billion — Indicates significant growth in the overall market Aktis is entering
- Aggregate transaction values in radiopharmaceuticals over 10 years: $33 billion — Reflects significant strategic investment and value creation in the sector
- S-1 filing date: 2025-12-19 — Marks the official commencement of the IPO process for Aktis Oncology
- FDA IND clearance for [225Ac]Ac-AKY-1189: 2025-04 — Enables the initiation of human investigational studies for their lead candidate
- Anticipated preliminary Phase 1b results: 2027-Q1 — Key near-term catalyst for investor evaluation of [225Ac]Ac-AKY-1189
Frequently Asked Questions
What are the latest SEC filings for Aktis Oncology, INC. (AKTS)?
Aktis Oncology, INC. has 1 recent SEC filings from Dec 2025, including 1 S-1. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AKTS filings?
Across 1 filings, the sentiment breakdown is: 1 mixed. The dominant sentiment is mixed.
Where can I find Aktis Oncology, INC. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Aktis Oncology, INC. (AKTS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Aktis Oncology, INC.?
Financial highlights for Aktis Oncology, INC. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for AKTS?
The investment thesis for AKTS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Aktis Oncology, INC.?
Key executives identified across Aktis Oncology, INC.'s filings include Matthew Roden, PhD.
What are the main risk factors for Aktis Oncology, INC. stock?
Of AKTS's 1 assessed filings, 1 were flagged high-risk, 0 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Aktis Oncology, INC.?
Forward guidance and predictions for Aktis Oncology, INC. are extracted from SEC filings as they are enriched.